Category: Amyotrophic Lateral Sclerosis (ALS)

Pridopidine for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for pridopidine for the treatment of ALS. Prilenia recently received a positive opinion from the Committee of Orphan Medicinal Products (COMP) in…